IP Library Granted Patent US 9,738,725
Granted Patent B2
US 9,738,725 · App. 14/166,251 · Granted Aug 22, 2017

Antibodies to TIP-1

Inventors: Dennis E. Hallahan (St. Louis, MO); Heping Yan (St. Louis, MO)
Assignees: WASHINGTON UNIVERSITY; VANDERBILT UNIVERSITY
C07K16/30A61B90/361A61K39/3955A61K49/0058A61K51/1045A61K51/1066A61K51/1093A61N5/10C07K16/18C07K16/3053A61N2005/1098C07K2317/34C07K2317/622C07K2317/73C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,738,725
App. No.
14/166,251
Granted
Aug 22, 2017
Kind
B2
Abstract

The present invention is directed towards isolated antibodies that bind to GRP78 and TIP-1.

Claims (8)

1. An isolated antibody that binds to Tax1-binding protein 3 (TIP-1), wherein the antibody comprises a heavy chain variable domain comprising a CDR1, CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:28, the heavy chain variable region CDR2 comprises SEQ ID NO:29, and the heavy chain variable region CDR3 comprises SEQ ID NO:30; and a light chain variable domain comprising a CDR1, CDR2, and a CDR3, wherein the light chain variable domain CDR1 comprises SEQ ID NO:31, the light chain variable region domain CDR2 comprises SEQ ID NO:32, and the light chain variable region domain CDR3 comprises SEQ ID NO:33.

2. The antibody of claim 1 , wherein the antibody is selected from the group consisting of a humanized antibody, a single chain variable fragment (scFv) antibody, an antigen-binding fragment, or a chimeric antibody.

3. The antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO:25 and a light chain variable region comprising SEQ ID NO:27.

4. The antibody of claim 1 , wherein the antibody recognizes the epitope of SEQ ID NO:21.

5. The antibody of claim 1 , wherein the antibody is conjugated directly or indirectly to a payload selected from the group consisting of a therapeutic agent, an imaging agent, or a combination thereof.

6. A method of enhancing radiotherapy in a subject, the method comprising administering a pharmacologically effective amount of an antibody of claim 5 to the subject, such that radiotherapy is enhanced.

7. The method of claim 6 , further comprising administering ionizing radiation to the subject.

8. The method of claim 6 , further comprising imaging the subject.

Assignments (4)
CONFIRMATORY LICENSE Recorded Mar 31, 2017
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042125/0988 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2015
From: YAN, HEPING
To: WASHINGTON UNIVERSITY; VANDERBILT UNIVERSITY
Reel/Frame 035125/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2015
From: HALLAHAN, DENNIS E.
To: WASHINGTON UNIVERSITY; VANDERBILT UNIVERSITY
Reel/Frame 034818/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2014
From: HALLAHAN, DENNIS; YAN, HEPING
To: WASHINGTON UNIVERSITY
Reel/Frame 032522/0468 →
Continuity (3)
Continuation In Part PCTUS2012048856 · Jul 30, 2012
Provisional Application 61513333 · Jul 29, 2011
Related Publication 20140316186A1 · Oct 23, 2014